利用效率前沿方法对齐斑块状银屑病生物制剂的价格与临床获益
该健康经济学评估采用效率前沿(EF)方法,比较美国、澳大利亚、加拿大、法国和德国11种生物制剂及2种生物类似药治疗斑块状银屑病的价格与临床获益。结果显示,美国生物制剂价格需中位降低71%才能与EF估计价格一致,降幅大于其他四国;除risankizumab外,EF价格低于传统成本效果分析价格。
要点
- 为对齐EF价格,美国药价需中位降低71%(IQR 31%-95%)。
- EF方法可替代传统CEA,尤其适用于有多种治疗选择的药物类别。
核心结论
- 采用EF方法谈判价格可大幅降低斑块状银屑病生物制剂价格,并使价格更好地与临床获益对齐。
研究设计与样本
- 健康经济学评估,采用EF方法比较美国、澳大利亚、加拿大、法国和德国11种生物制剂和2种生物类似药的价格与临床获益。
- 数据收集于2023年2月至3月,分析于2023年3月至6月。
主要发现
- 13种生物制剂PASI 90应答率范围为17.9%(etanercept)至71.6%(risankizumab)。
- 美国药价需中位降低71%(IQR 31%-95%)以对齐EF价格;加拿大需降低41%(6%-57%),澳大利亚36%(0%-65%),法国19%(0%-67%),德国11%(8%-26%)。
关键数值与推荐
- EF基于PASI 90应答率和截至2023年1月的年治疗费用构建;美国费用为扣除估计制造商返利后的净价。
- EF价格与临床与经济评价研究所(ICER)以每质量调整生命年15万美元阈值的传统CEA价格进行比较。
- 除risankizumab外,EF价格低于传统CEA价格。
临床怎么用
- 美国政策制定者可考虑使用EF方法谈判价格,使价格与比较临床获益相称。
- EF方法尤其适用于有多种治疗替代且差异可由单一结局指标充分总结的药物类别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles. The efficiency frontier (EF) method offers policymakers an alternative approach. OBJECTIVE: To assess how the EF approach could align prices and clinical benefits of biologic medications for plaque psoriasis and estimate price reductions in the US vs 4 peer countries: Australia, Canada, France, and Germany. DESIGN AND SETTING: This health economic evaluation used the EF approach to compare the prices and clinical benefits of 11 biologics and 2 biosimilars for plaque psoriasis in the US, Australia, Canada, France, and Germany. Data were collected from February to March 2023 and analyzed from March to June 2023. MAIN OUTCOME MEASURES: EFs were constructed based on each biologic's efficacy, measured using the Psoriasis Area and Severity Index (PASI) 90 response rate, and annual treatment cost as of January 2023; US costs were net of estimated manufacturer rebates. Prices based on the EF were compared with traditional CEA-based prices calculated by the Institute for Clinical and Economic Review at a threshold of $150 000 per quality-adjusted life-year gained. RESULTS: Among 13 biologics, PASI 90 response rates ranged from 17.9% (etanercept) to 71.6% (risankizumab); US net annual treatment costs ranged from $1664 (infliximab-dyyb) to $79 277 (risankizumab). The median (IQR) net annual treatment cost was higher in the US ($34 965 [$20 493-$48 942]) than prerebate costs in Australia ($9179 [$6691-$12 688]), Canada ($15 556 [$13 017-$16 112]), France ($9478 [$6637-$11 678]), and Germany ($13 829 [$13 231-$15 837]). The US EF included infliximab-dyyb (PASI 90: 57.4%; annual cost: $1664), ixekizumab (PASI 90: 70.8%; annual cost: $33 004), and risankizumab (PASI 90: 71.6%; annual cost: $79 277). US prices for psoriasis biologics would need to be reduced by a median (IQR) of 71% (31%-95%) to align with those estimated using the EF; the same approach would yield smaller price reductions in Canada (41% [6%-57%]), Australia (36% [0%-65%]), France (19% [0%-67%]), and Germany (11% [8%-26%]). Except for risankizumab, the EF-based prices were lower than the prices based on traditional CEA. CONCLUSIONS AND RELEVANCE: This economic evaluation showed that for plaque psoriasis biologics, using an EF approach to negotiate prices could lead to substantial price reductions and better align prices with clinical benefits. US policymakers might consider using EFs to achieve prices commensurate with comparative clinical benefits, particularly for drug classes with multiple therapeutic alternatives for which differences can be adequately summarized by a single outcome measurement.
引用
- Egilman AC, Kesselheim AS, Avorn J, et al. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis. JAMA Dermatol. 2024. PMID: 38381418. doi:10.1001/jamadermatol.2023.6236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。